1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,308 | 0,322 | 11:57 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SPRINT BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 13.05. | Sprint Bioscience AB Q1 Loss Widens | 1 | RTTNews | ||
| 16.04. | Sprint Bioscience AB: Sprint Bioscience completes strategic STK25 evaluation; continued focus on the primary indication | 185 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announces the conclusion of a targeted evaluation of the STK25 program, conducted in partnership with the Experimental Drug Development Centre (EDDC), Singapore's national... ► Artikel lesen | |
| 01.04. | Sprint Bioscience AB: Sprint Bioscience appoints Jenni Björnulfson as CFO | 156 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announces that Jenni Björnulfson has been appointed chief Financial Officer (CFO) of the company. With extensive and diverse experience in both life science and finance... ► Artikel lesen | |
| 01.04. | Sprint Bioscience AB: Positive results expand the NNMT program into Chronic Kidney Disease | 167 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announces positive results from its NNMT program from a proof-of-concept study demonstrating therapeutic potential in Chronic Kidney Disease (CKD). Based on these findings... ► Artikel lesen | |
| 17.03. | Sprint Bioscience AB: Sprint Bioscience reports positive results from the VRK1 program | 203 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announces positive results from a pre-clinical proof-of-concept (POC) study performed within the company's VRK1 program. The results show that VRK1 inhibition selectively... ► Artikel lesen | |
| 24.11.25 | Sprint Bioscience Announces Sale Of TREX1 Program to Gilead Sciences | 946 | AFX News | FOSTER CITY (dpa-AFX) - Sprint Bioscience AB (SPRINT.ST) announced the sale of its TREX1 cancer program to Gilead Sciences. The deal includes an upfront payment of $14 million, as well as potential... ► Artikel lesen |
6 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 14,200 | +3,65 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,640 | +1,23 % | COSCIENS Biopharma Inc. Reports Q1 2026 Results | TORONTO, ONTARIO, May 12, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company") today reported its financial and operating results for the first... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 61,62 | -0,71 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 5,000 | +2,67 % | AbCellera Biologics Inc. - 8-K, Current Report | ||
| GLOW LIFETECH | 0,020 | -23,08 % | Glow Lifetech Corp.: Glow Lifetech Achieves Warrant-Free Capital Structure Following Elimination of 70 Million Warrants and 20% Reduction in Fully Diluted Shares | Toronto, Ontario--(Newsfile Corp. - June 2, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce that all of its outstanding 8,900,000... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 257,80 | +0,94 % | ROUNDUP/'WSJ': US-Investor Elliot steigt bei Sartorius-Großaktionär Bio-Rad ein | NEW YORK (dpa-AFX) - Der US-Investor Elliott hat laut einem Medienbericht eine beachtliche Beteiligung an dem Sartorius-Großaktionär Bio-Rad Laboratories aufgebaut. Der aktivistische Investor wolle... ► Artikel lesen | |
| AVID BIOSERVICES | - | - | Avid Bioservices Appoints Maria Ebro Andreasen as Chief People Officer to Fuel Continued Growth and Talent Strategy | Company expands team, university partnerships, and internship programs to build long-term biologics talent pipeline.TUSTIN, Calif., May 18, 2026 /PRNewswire/ -- Avid Bioservices, a leading... ► Artikel lesen | |
| BIOLINERX | 2,560 | -3,03 % | BioLineRx Ltd.: BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update | - Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) -
- Announced new GLIX1 data demonstrating potent anti-tumor... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 3,500 | -4,37 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Presents Real-World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026 | SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC
SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas... ► Artikel lesen | |
| PARATEK PHARMACEUTICALS | - | - | Paratek Pharmaceuticals: $1.3 Billion Financing Supports Radius Health Combination To Build Specialty Pharma Platform | ||
| MINERVA NEUROSCIENCES | 4,184 | +4,29 % | Minerva Neurosciences, Inc: Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs | Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategyBURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| OVID THERAPEUTICS | 2,120 | +1,92 % | Ovid Therapeutics Inc.: Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors | NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant... ► Artikel lesen | |
| COCRYSTAL | 0,850 | +0,59 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer | BOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet... ► Artikel lesen | |
| APPLIED THERAPEUTICS | 0,077 | 0,00 % | Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics | Cycle Group Holdings Limited ("Cycle") is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ: APLT; "Applied"), a clinical-stage biopharmaceutical... ► Artikel lesen | |
| GEOVAX LABS | 1,630 | -1,21 % | EQS-News: GeoVax, Inc.: GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation | EQS-News: GeoVax, Inc.
/ Key word(s): Science
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation 03.06.2026 / 15:06 CET/CEST
The... ► Artikel lesen |
Das Unternehmen SPRINT BIOSCIENCE AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,325 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPRINT BIOSCIENCE AB finden Sie auf Wallstreet Online.